Key result
After adjustment for age and risk factors, bicuspid aortic valve was independently associated with faster haemodynamic progression of aortic stenosis compared to TAV.
Why the study?
It was unknown whether progression of aortic stenosis differs between patients with bicuspid aortic valve and those with tricuspid aortic valve.
Does bicuspid aortic valve phenotype accelerate the progression of aortic stenosis compared to tricuspid aortic valve in patients with mild-to-moderate AS?
Cohort (n=141)
Does bicuspid aortic valve phenotype accelerate the progression of aortic stenosis compared to tricuspid aortic valve in patients with mild-to-moderate AS?
In patients with mild-to-moderate aortic stenosis, a bicuspid aortic valve is independently associated with faster hemodynamic and anatomic progression compared to a tricuspid valve when adjusted for age and risk profile.
Answers are grounded in this paper and cite their sources.
Supports closer surveillance in BAV patients with mild-moderate AS; leaves open whether phenotype-specific thresholds should guide timing of intervention.
AIMS: To compare the progression of aortic stenosis (AS) in patients with bicuspid aortic valve (BAV) or tricuspid aortic valve (TAV). METHODS AND RESULTS: One hundred and forty-one patients with mild-to-moderate AS, recruited prospectively in the PROGRESSA study, were included in this sub-analysis. Baseline clinical, Doppler echocardiography and multidetector computed tomography characteristics were compared between BAV (n = 32) and TAV (n = 109) patients. The 2-year haemodynamic [i.e. peak aortic jet velocity (Vpeak) and mean transvalvular gradient (MG)] and anatomic [i.e. aortic valve calcification density (AVCd) and aortic valve calcification density ratio (AVCd ratio)] progression of AS were compared between the two valve phenotypes. The 2-year progression rate of Vpeak was: 16 (-0 to 40) vs. 17 (3-35) cm/s, P = 0.95; of MG was: 1.8 (-0.7 to 5.8) vs. 2.6 (0.4-4.8) mmHg, P = 0.56; of AVCd was 32 (2-109) vs. 52 (25-85) AU/cm2, P = 0.15; and of AVCd ratio was: 0.08 (0.01-0.23) vs. 0.12 (0.06-0.18), P = 0.16 in patients with BAV vs. TAV. In univariable analyses, BAV was not associated with AS progression (all, P ≥ 0.26). However, with further adjustment for age, AS baseline severity, and several risk factors (i.e. sex, history of hypertension, creatinine level, diabetes, metabolic syndrome), BAV was independently associated with faster haemodynamic (Vpeak: β = 0.31, P = 0.02) and anatomic (AVCd: β = 0.26, P = 0.03 and AVCd ratio: β = 0.26, P = 0.03) progression of AS. CONCLUSION: In patients with mild-to-moderate AS, patients with BAV have faster haemodynamic and anatomic progression of AS when compared to TAV patients with similar age and risk profile. This study highlights the importance and necessity to closely monitor patients with BAV and to adequately control and treat their risk factors. CLINICAL TRIAL REGISTRATION: https://clinicaltrials.gov Unique identifier: NCT01679431.
No takes yet. Share an insight, caveat, or question.
Shen et al. (2020) conducted a cohort in Aortic stenosis (n=141). Bicuspid aortic valve (BAV) vs. Tricuspid aortic valve (TAV) was evaluated on 2-year haemodynamic progression of AS (peak aortic jet velocity) (β = 0.31, p=0.02). After adjustment for age and risk factors, bicuspid aortic valve was independently associated with faster haemodynamic progression of aortic stenosis compared to TAV.
Synapse has enriched 10 related papers. Consider them for comparative context: